Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
Madeline SingerSami KhellaShawn BirdPaul McIntoshBandhu PaudyalAnil WadhwaniColin C QuinnChafic KaramPublished in: Muscle & nerve (2023)
This study found efgartigimod to be efficacious, well tolerated, and safe in patients with MG. Efgartigimod should be considered as an add-on therapy, a bridge therapy, or as a monotherapy if patients have difficulty tolerating other treatments.